WO2003026650A1 - 3-(heteroarylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors - Google Patents

3-(heteroarylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors Download PDF

Info

Publication number
WO2003026650A1
WO2003026650A1 PCT/US2002/030922 US0230922W WO03026650A1 WO 2003026650 A1 WO2003026650 A1 WO 2003026650A1 US 0230922 W US0230922 W US 0230922W WO 03026650 A1 WO03026650 A1 WO 03026650A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
dihydro
indol
methylene
pyrazol
Prior art date
Application number
PCT/US2002/030922
Other languages
English (en)
French (fr)
Inventor
Steven W. Andrews
Julie A. Wurster
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of WO2003026650A1 publication Critical patent/WO2003026650A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/US2002/030922 2001-09-27 2002-09-27 3-(heteroarylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors WO2003026650A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32581701P 2001-09-27 2001-09-27
US32581601P 2001-09-27 2001-09-27
US60/325,817 2001-09-27
US60/325,816 2001-09-27

Publications (1)

Publication Number Publication Date
WO2003026650A1 true WO2003026650A1 (en) 2003-04-03

Family

ID=26985127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/030922 WO2003026650A1 (en) 2001-09-27 2002-09-27 3-(heteroarylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors

Country Status (2)

Country Link
US (3) US7005444B2 (US06559173-20030506-C00003.png)
WO (1) WO2003026650A1 (US06559173-20030506-C00003.png)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009547A1 (de) * 2002-07-23 2004-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg In 6-stellung substituierte indolinonderivate, ihre herstellung und ihre verwendung als arzneimittel
WO2004009546A1 (de) * 2002-07-23 2004-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg In 6-stellung substituierte indolinonderivate, ihre herstellung und ihre verwendung als arzneimittel
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US20070059381A1 (en) * 2003-06-20 2007-03-15 Barker Ronnie C Treatment of amd with combination of ingredients
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8455656B2 (en) * 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
AU2006268265A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Kinase inhibitors
US7309787B2 (en) * 2005-07-13 2007-12-18 Allergan, Inc. Kinase inhibitors
CA2602453A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Kinase inhibitors
US7749530B2 (en) 2005-07-13 2010-07-06 Allergan, Inc. Kinase inhibitors
US8338415B2 (en) 2006-01-24 2012-12-25 Allergan, Inc. Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
US7977351B2 (en) * 2006-03-22 2011-07-12 Allergan, Inc. Heteroaryl dihydroindolones as kinase inhibitors
US8034957B2 (en) * 2006-08-11 2011-10-11 Allergan, Inc. Kinase inhibitors
US8143410B2 (en) 2006-11-16 2012-03-27 Allergan, Inc. Kinase inhibitors
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
MX2014002890A (es) 2011-09-12 2015-01-19 Bayer Cropscience Lp Metodo para mejorar la salud y/o promover el crecimiento de una planta y/o mejorar la maduracion de frutos.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056710A1 (en) * 1999-03-04 2000-09-28 Glaxo Group Limited 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors
DE19924401A1 (de) * 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
CA2078214C (en) 1990-04-02 1995-03-28 Robert Lee Dow Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
CA2108889A1 (en) 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
RU2155187C2 (ru) 1992-08-06 2000-08-27 Варнер-Ламберт Компани Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека.
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
EP1117397A1 (en) 1998-08-31 2001-07-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056710A1 (en) * 1999-03-04 2000-09-28 Glaxo Group Limited 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors
DE19924401A1 (de) * 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009547A1 (de) * 2002-07-23 2004-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg In 6-stellung substituierte indolinonderivate, ihre herstellung und ihre verwendung als arzneimittel
WO2004009546A1 (de) * 2002-07-23 2004-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg In 6-stellung substituierte indolinonderivate, ihre herstellung und ihre verwendung als arzneimittel
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
EA008623B1 (ru) * 2002-07-23 2007-06-29 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Замещённые в положении 6 индолиноновые производные, их получение и их применение в качестве лекарственных средств
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7547703B2 (en) 2002-07-23 2009-06-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments
US7858616B2 (en) 2002-07-23 2010-12-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments

Also Published As

Publication number Publication date
US7005444B2 (en) 2006-02-28
US20030130328A1 (en) 2003-07-10
US7393870B2 (en) 2008-07-01
US6559173B1 (en) 2003-05-06
US20060074116A1 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
US7393870B2 (en) 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
US6541504B1 (en) (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
US6747025B1 (en) Kinase inhibitors for the treatment of disease
US7309787B2 (en) Kinase inhibitors
CA2461812C (en) 3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
AU2002341881A1 (en) 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US6699863B1 (en) Kinase inhibitors for the treatment of disease
EP1902025A1 (en) Kinase inhibitors
WO2013062843A1 (en) Pyridine- sulfoximines as tyrosine kinase inhibitors
EP1490356B1 (en) (3z)-3-(3-hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
US7439371B2 (en) Indol kinase inhibitors
US8455529B2 (en) Kinase inhibitors
WO2004050621A2 (en) Indol derivatives and their use as kinase inhibitors
JP2011225582A (ja) 疾患の治療のためのキナーゼ阻害剤
WO2003027109A1 (en) 3-(heteroarylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP